控释息宁（CR4）与标准息宁（25毫克/100毫克）治疗晚期帕金森病的比较：一项双盲交叉研究。 - Suppr

Suppr

超能文献

Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.

作者信息

Sage J I, Mark M H

机构信息

Department of Neurology, UMDNJ--Robert Wood Johnson Medical School, New Brunswick 08903.

出版信息

Clin Neuropharmacol. 1988 Apr;11(2):174-9. doi: 10.1097/00002826-198804000-00009.

DOI:10.1097/00002826-198804000-00009

PMID:3378226

Abstract

摘要

相似文献

Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.控释息宁（CR4）与标准息宁（25毫克/100毫克）治疗晚期帕金森病的比较：一项双盲交叉研究。

Clin Neuropharmacol. 1988 Apr;11(2):174-9. doi: 10.1097/00002826-198804000-00009.

Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease.控释息宁（CR-4）：一项针对帕金森病症状波动患者的双盲交叉研究。

Mayo Clin Proc. 1988 Sep;63(9):876-86. doi: 10.1016/s0025-6196(12)62690-1.

Controlled-release carbidopa/levodopa in the treatment of Parkinsonism.控释卡比多巴/左旋多巴治疗帕金森病

Clin Neuropharmacol. 1984;7(2):135-9. doi: 10.1097/00002826-198406000-00003.

Sinemet CR in Parkinson's disease.息宁控释片治疗帕金森病

Nebr Med J. 1991 Jan;76(1):8-10.

Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.帕金森病伴或不伴运动波动患者使用控释卡比多巴/左旋多巴（CR4-息宁）的情况

Neurology. 1988 Jul;38(7):1143-6. doi: 10.1212/wnl.38.7.1143.

Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.控释左旋多巴/卡比多巴。III：息宁控释片治疗帕金森病的疗效波动

Clin Neuropharmacol. 1988 Apr;11(2):168-73.

Sinemet in Parkinson's disease: efficacy with and without food.息宁在帕金森病中的应用：进食与不进食时的疗效

Clin Neuropharmacol. 1986;9(2):196-9.

Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).控释左旋多巴/卡比多巴（息宁控释片）长期治疗的结果。

J Neural Transm Park Dis Dement Sect. 1990;2(3):205-13. doi: 10.1007/BF02257651.

Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease.左旋多巴控释片（CR4 50/200）与左旋多巴25/100治疗帕金森病的随机双盲交叉研究。

Eur Neurol. 1990;30(2):75-8. doi: 10.1159/000117314.

Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.控释左旋多巴/卡比多巴。I. 息宁控释片治疗帕金森病的疗效波动

Neurology. 1987 Feb;37(2):233-41. doi: 10.1212/wnl.37.2.233.

引用本文的文献

Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations.帕金森病运动波动患者转换为缓释卡比多巴-左旋多巴（ER CD-LD）即IPX066过程中的给药模式。

Parkinsons Dis. 2018 Oct 22;2018:9763057. doi: 10.1155/2018/9763057. eCollection 2018.

Levodopa in Parkinson's Disease: Current Status and Future Developments.左旋多巴在帕金森病中的应用：现状与未来发展。

Curr Neuropharmacol. 2018;16(8):1239-1252. doi: 10.2174/1570159X15666170510143821.

Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.缓释卡比多巴-左旋多巴（IPX066）用于早期和晚期帕金森病的长期治疗：一项为期9个月的开放标签扩展试验。

CNS Drugs. 2015 Apr;29(4):341-50. doi: 10.1007/s40263-015-0242-2.

Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.治疗帕金森病患者左旋多巴诱导运动障碍的药物策略。

CNS Drugs. 2014 Dec;28(12):1155-84. doi: 10.1007/s40263-014-0205-z.

International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease.左旋多巴控释片与标准美多芭（25/100）治疗170例帕金森病症状波动患者的国际（荷兰-英国）双盲研究

J Neurol. 1996 Mar;243(3):235-40. doi: 10.1007/BF00868520.

Diagnosis and treatment of Parkinson's disease in the elderly.老年帕金森病的诊断与治疗

J Gen Intern Med. 1994 Oct;9(10):583-9. doi: 10.1007/BF02599289.

A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.左旋多巴控释片4与标准左旋多巴25/100对帕金森病伴运动功能波动患者的双盲交叉对照研究

J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):207-12. doi: 10.1136/jnnp.52.2.207.

Current drug therapy for Parkinson's disease. A review.

Drugs Aging. 1992 Mar-Apr;2(2):112-24. doi: 10.2165/00002512-199202020-00005.

Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.在使用控释左旋多巴/卡比多巴进行维持治疗期间，在病情改善的背景下，耐受性的客观证据。

Eur J Clin Pharmacol. 1992;43(5):483-9. doi: 10.1007/BF02285089.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验